Search results for "Bisphosphonate-Associated Osteonecrosis"

showing 10 items of 66 documents

Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zole…

2008

Abstract Background In addition to other treatments, patients with prostate cancer (pCA) and bone metastasis receive bisphosphonates. Since 2003, a previously unknown side-effect of bisphosphonates—bisphosphonate-associated osteonecrosis of the jaws (BP-ONJ)—has been described, and frequency has since increased. An exact incidence is still unknown. Objectives The aim of this study was to assess the incidence and additional factors in the development of BP-ONJ. Design, setting, and participants From July 2006 to October 2007, patients with advanced pCA and osseous metastasis receiving bisphosphonate therapy in the Department of Urology or Haematology and Oncology at the Johannes-Gutenberg-Un…

Malemedicine.medical_specialtyUrologymedicine.medical_treatmentBone NeoplasmsZoledronic AcidProstate cancerRisk FactorsInternal medicineGermanymedicinePrevalenceHumansProspective cohort studyAgedRetrospective StudiesBisphosphonate-associated osteonecrosis of the jawBone Density Conservation AgentsDiphosphonatesbusiness.industryIncidence (epidemiology)ImidazolesOsteonecrosisBone metastasisProstatic NeoplasmsRetrospective cohort studyBisphosphonateMiddle Agedmedicine.diseasePrognosisSurgeryZoledronic acidCross-Sectional StudiesInjections IntravenousbusinessJaw Diseasesmedicine.drugFollow-Up StudiesEuropean urology
researchProduct

Prevalence of bisphosphonate associated osteonecrosis of the jaws in multiple myeloma patients

2010

Abstract Background Bisphosphonate-associated osteonecrosis of the jaws (BP-ONJ) is an adverse effect of bisphosphonate treatment with varying reported incidence rates. Methods In two neighboring German cities, prevalence and additional factors of the development of BP-ONJ in multiple myeloma patients with bisphosphonates therapy were recorded using a retrospective (RS) and cross-sectional study (CSS) design. For the RS, all patients treated from Jan. 2000 - Feb. 2006 were contacted by letter. In the CSS, all patients treated from Oct. 2006 - Mar. 2008 had a physical and dental examination. Additionally, a literature review was conducted to evaluate all articles reporting on BP-ONJ prevalen…

Malemedicine.medical_specialtylcsh:Specialties of internal medicineTreatment outcomeClinical NeurologyBisphosphonate-Associated Osteonecrosisstomatognathic systemlcsh:RC581-951medicinePrevalenceHumansAdverse effectGeneral DentistryMultiple myelomaAgedRetrospective StudiesAged 80 and overBone Density Conservation AgentsDiphosphonatesbusiness.industryDentistry(all)ResearchOsteonecrosisRetrospective cohort studyMiddle Agedmedicine.diseaseDermatologySurgerystomatognathic diseasesCross-Sectional StudiesTreatment OutcomeOtorhinolaryngologyOral and maxillofacial surgeryHead and neck surgeryFemaleNeurology (clinical)businessMultiple MyelomaBisphosphonate treatmentHead & Face Medicine
researchProduct

Exposed necrotic bone in 183 patients with bisphosphonate-related osteonecrosis of the jaw: Associated clinical characteristics

2017

The main objective of our study was to identify oral symptoms and signs most likely to be associated with the exposure of necrotic bone in bisphosphonate-related osteonecrosis of the jaw (BRONJ). The study group consisted of 183 patients with BRONJ. We recorded data on the underlying disease, bisphosphonate used, location of osteonecrosis, symptoms, pain, fistula development, suppuration, infection, exposed necrotic bone, and BRONJ stage. The mean age of the patients was 68.22 ± 12.19 years. The sample included 118 (64.5%) women. Breast cancer and multiple myeloma were the most common underlying diseases, and 50 patients received oral bisphosphonates for osteoporosis. Dental extractions (69…

Malemedicine.medical_specialtymedicine.medical_treatmentFistulaOsteoporosisOdontologíaMaxilares03 medical and health sciencesNecrosis0302 clinical medicineBreast cancermedicineHumansStage (cooking)General DentistryMultiple myelomaUNESCO:CIENCIAS MÉDICASAgedRetrospective StudiesOral Medicine and Pathologybusiness.industryResearchRetrospective cohort study030206 dentistryBisphosphonatemedicine.diseaseSurgeryOtorhinolaryngology030220 oncology & carcinogenesisBisphosphonate-Associated Osteonecrosis of the JawFemaleSurgerySymptom AssessmentOsteonecrosis of the jawbusiness
researchProduct

Medication-related osteonecrosis of the jaw associated with bisphosphonates and denosumab in osteoporosis

2016

OBJECTIVE: To describe the clinical characteristics and evolution of our series of medication-related osteonecrosis of the jaws (MRONJ) associated with denosumab in osteoporotic patients. MATERIAL AND METHODS: We present 10 new cases of MRONJ in patients receiving denosumab for osteoporosis. We describe the mean doses of denosumab, previous bisphosphonate intake, and the clinical characteristics associated with the osteonecrosis, such as local contributing factors, symptoms, and evolution after treatment. RESULTS: The mean number of denosumab doses was 3.4 2.2. In 90% of patients, there was a prior history of oral bisphosphonate intake, with a mean duration of 46.78 25.11 months. The most c…

Malemedicine.medical_specialtymedicine.medical_treatmentOsteoporosisDentistryOdontología03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansStage (cooking)General DentistryAgedSclerosisMedicamentoBisphosphonate-associated osteonecrosis of the jawBone Density Conservation AgentsDiphosphonatesbusiness.industry030206 dentistryMiddle AgedBisphosphonatemedicine.diseaseBone Density Conservation AgentsDenosumabOtorhinolaryngologyDental extraction030220 oncology & carcinogenesisOsteoporosisBisphosphonate-Associated Osteonecrosis of the JawFemaleDenosumabTomography X-Ray ComputedOsteonecrosis of the jawbusinessmedicine.drugOral Diseases
researchProduct

BRONJ in patients with rheumatoid arthritis: A multicenter case series

2016

Objective: Osteonecrosis of the jaw (ONJ) is a potentially severe adverse effect of various medications (bisphosphonates, anti-resorptive, and anti-angiogenic drugs). ONJ pathogenesis is still unclear although some risk factors have been recognized. Of these, rheumatoid arthritis (RA) has been hypothesized as a potential risk factor for developing ONJ. This observational study will describe a multicenter case series of patients affected with RA and ONJ, and it will attempt to evaluate the association between features of ONJ and pharmacological, systemic, and site variables. Methods: Demographic, pharmacological, and clinical data from 18 RA patients with ONJ were collected and registered fr…

Malemedicine.medical_specialtymedicine.medical_treatmentOsteoporosisONJArthritis Rheumatoid03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansBisphosphonateONJ; Bisphosphonate; Denosumab; Jaw; Osteonecrosis; Osteoporosis; Rheumatoid arthritis; Dentistry (all); Otorhinolaryngology2734 Pathology and Forensic MedicineRheumatoid arthritisAdverse effectGeneral DentistryRheumatoid arthritiAgedBisphosphonate-associated osteonecrosis of the jawbusiness.industryOtorhinolaryngology2734 Pathology and Forensic MedicineOsteoporosiOsteonecrosis030206 dentistryBisphosphonateMiddle Agedmedicine.diseaseSurgeryDenosumabOtorhinolaryngologyJaw030220 oncology & carcinogenesisRheumatoid arthritisOsteonecrosiDentistry (all)OsteoporosisMethotrexateBisphosphonate-Associated Osteonecrosis of the JawFemaleDenosumabbusinessOsteonecrosis of the jawmedicine.drug
researchProduct

Serum levels of RANKL and OPG, and the RANKL/OPG ratio in bisphosphonate-related osteonecrosis of the jaw: Are they useful biomarkers for the advance…

2017

We determined whether serum levels of Receptor Activator for Nuclear Factor κ B Ligand (RANKL), Osteoprotegerin (OPG), and the RANKL/OPG ratio could be useful biomarkers for the severity of oral lesions in bisphosphonate-related osteonecrosis of the jaw (BRONJ). A case-control study in which Group 1 consisted of 41 patients with BRONJ due to bisphosphonates, and Group 2 consisted of 44 healthy control cases. The plasma levels of RANKL and OPG were analyzed by an ELISA assay. The OPG/RANKL ratio was also calculated. We determined if the mean serum values differed among the different stages of BRONJ. Serum levels of RANKL were lower in Group 1 than in Group 2 (p =0.01), and serum levels of OP…

Malemusculoskeletal diseases0301 basic medicinemedicine.medical_specialtyNecrosismedicine.medical_treatmentOdontologíaSeverity of Illness IndexNecrosis03 medical and health sciences0302 clinical medicineOsteoprotegerinInternal medicinemedicineHumansReceptorGeneral DentistryUNESCO:CIENCIAS MÉDICASAgedOral Medicine and PathologyBisphosphonate-associated osteonecrosis of the jawbiologybusiness.industryResearchRANK LigandOsteoprotegerinCase-control studyBisphosphonatemedicine.disease030104 developmental biologyEndocrinologyOtorhinolaryngologyRANKLCase-Control Studies030220 oncology & carcinogenesisDisease Progressionbiology.proteinBisphosphonate-Associated Osteonecrosis of the JawFemaleSurgerymedicine.symptomOsteonecrosis of the jawbusinessBiomarkersMedicina Oral Patología Oral y Cirugia Bucal
researchProduct

Osteonecrosis of the jaw induced by receptor activator of nuclear factor-kappa B ligand (Denosumab) - Review.

2015

Background Denosumab, an anti-resorptive agent, IgG2 monoclonal antibody for human Receptor activator of nuclear factor-kappa B ligand (RANKL), has been related to the occurrence of osteonecrosis of the jaws. Thus, the aim of this study was to review the literature from clinical case reports, regarding the type of patient and the therapeutic approach used for osteonecrosis of the jaws induced by chronic use of Denosumab. Material and Methods For this, a literature review was performed on PubMed, Medline and Cochrane databases, using the keywords “Denosumab” “anti-RANK ligand” and “Osteonecrosis of jaw”. To be included, articles should be a report or a serie of clinical cases, describing pat…

OncologyMalemedicine.medical_specialtyOsteoporosisOdontologíaReview03 medical and health sciencesTherapeutic approachProstate cancer0302 clinical medicineDiabetes mellitusInternal medicinemedicineHumansGeneral DentistryAgedBisphosphonate-associated osteonecrosis of the jawOral Medicine and PathologybiologyBone Density Conservation AgentsDiphosphonatesbusiness.industryRANK LigandNF-kappa BOsteonecrosis030206 dentistryMiddle Aged:CIENCIAS MÉDICAS [UNESCO]medicine.diseaseCiencias de la saludSurgeryDenosumabOtorhinolaryngologyRANKL030220 oncology & carcinogenesisUNESCO::CIENCIAS MÉDICASbiology.proteinSurgeryBisphosphonate-Associated Osteonecrosis of the JawFemaleDenosumabbusinessOsteonecrosis of the jawmedicine.drugMedicina oral, patologia oral y cirugia bucal
researchProduct

Medication-related osteonecrosis of the jaw in a cancer patient receiving lenvatinib.

2018

Medication-related osteonecrosis of the jaw (MRONJ) is an adverse drug reaction that affects the mandible and maxilla of patients exposed to bone-targeting agents such as anti-resorptive and anti-angiogenic agents. Several MRONJ cases have been reported after dental extractions in patients under treatment with anti-angiogenic agents, including receptor activator of nuclear factor κB ligand (RANKL) inhibitor, anti-vascular endothelial growth factor (anti-VEGF) monoclonal antibody, mammalian target of rapamycin (mTOR) inhibitors, and tyrosine kinase inhibitors (TKIs). The aim of this article was to describe an original case of lenvatinib-related osteonecrosis of the jaw in a patient affected …

OncologyMalemedicine.medical_specialtymedicine.medical_treatmentlenvatinibMRONJ03 medical and health scienceschemistry.chemical_compound0302 clinical medicineSettore MED/28 - Malattie OdontostomatologicheInternal medicinemedicineAnimalsHumansThyroid cancerbiologyBone Density Conservation AgentsDiphosphonatesbusiness.industryPhenylurea CompoundsOsteonecrosis030206 dentistryMiddle Agedmedicine.diseaseosteonecrosis of the jawOtorhinolaryngologyDental extractionchemistryRANKL030220 oncology & carcinogenesisConcomitantbiology.proteinQuinolinesSurgeryBisphosphonate-Associated Osteonecrosis of the Jawdental extractionOral SurgerybusinessLenvatinibOsteonecrosis of the jawTyrosine kinaseAdverse drug reactionInternational journal of oral and maxillofacial surgery
researchProduct

Biomarkers to predict the onset of biphosphonate-related osteonecrosis of the jaw: A systematic review

2019

Background: The goal of this paper was to identify available biomarkers to predict the onset of biphosphonate-related osteonecrosis of the jaw (BRONJ). Material and Methods: Case-control studies comparing the different concentrations of a series of molecules detected in serum and urine as matrices of BRONJ affected patients vs. non-affected were included. PRISMA guidelines for systematic reviews were used for the present paper. Two reviewers independently screened electronic databases (Medline, Web of science, and The Cochrane Library) and performed hand searches. Risk of bias assessment of selected studies was performed by the Newcastle-Ottawa Scale. This study is registered as PROSPERO CR…

Oncologymedicine.medical_specialtyMEDLINEReviewCochrane LibraryRisk Assessment03 medical and health sciences0302 clinical medicineBiphosphonatePredictive Value of TestsInternal medicinemedicineHumansGeneral DentistryOral Medicine and PathologyBisphosphonate-associated osteonecrosis of the jawbusiness.industryCase-control study030206 dentistrymedicine.disease:CIENCIAS MÉDICAS [UNESCO]Systematic reviewOtorhinolaryngologyCase-Control Studies030220 oncology & carcinogenesisUNESCO::CIENCIAS MÉDICASBisphosphonate-Associated Osteonecrosis of the JawSurgerybusinessRisk assessmentOsteonecrosis of the jawBiomarkers
researchProduct

Definition and estimation of osteonecrosis of jaw (ONJ), and optimal duration of antiresorptive treatment in bone metastatic cancer patients: supplem…

2017

To the Editor, In their recent article, Stopeck et al. [1] concluded that denosumab confirms its known safety profile even after longterm exposure, or after switching to it from zoledronic acid, and that osteonecrosis of jaws (ONJ) rates increased with increasing exposure to antiresorptives, consistent with previous reports. This is based on the open label extension phase of two phase 3 studies in patients with breast and prostate cancer with bone metastases who were randomized to receive denosumab or zoledronic acid (ZA) [2, 3]. The patients were offered open-label denosumab for up to an additional 2 years after the results of the primary analysis, favorable for denosumab on several aspect…

Oncologymedicine.medical_specialtyPopulationlaw.invention03 medical and health sciencesProstate cancer0302 clinical medicineBreast cancerRandomized controlled triallawInternal medicineNeoplasmsmedicineHumanseducationLetter to the Editoreducation.field_of_studyBisphosphonate-associated osteonecrosis of the jawBone Density Conservation AgentsDiphosphonatesbusiness.industryOsteonecrosisCancer030206 dentistrymedicine.diseaseSurgeryDenosumabZoledronic acidOncology030220 oncology & carcinogenesisBisphosphonate-Associated Osteonecrosis of the JawDenosumabOncology osteonecrosis denosumab metastatic cancer patientsbusinessJaw Diseasesmedicine.drug
researchProduct